Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (24)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Dean, S.W.
Right arrow Articles by Thybaud, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dean, S.W.
Right arrow Articles by Thybaud, V.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Mutagenesis, Vol. 14, No. 1, 141-151, January 1999
© 1999 UK Environmental Mutagen Society/Oxford University Press

Review

Transgenic mouse mutation assay systems can play an important role in regulatory mutagenicity testing in vivo for the detection of site-of-contact mutagens

S.W. Dean1,7, T.M. Brooks1, B. Burlinson2, J. Mirsalis3, B. Myhr4, L. Recio5 and V. Thybaud6

1 Covance Laboratories Ltd, Otley Road, Harrogate HG3 1PY, UK, 2 Glaxo Wellcome, Park Road, Ware SG12 0DJ, UK, 3 SRI International, Toxicology Laboratory, 333 Ravenswood Avenue, Menlo Park, CA 94025-3493, USA, 4 Covance Laboratories Inc., 9200 Leesburg Pike, Vienna, VA 22182, USA, 5 CIIT, Research Triangle Park, NC 27709, USA and 6 Rhone Poulenc Rorer, Alfortville, 14 94403 Vitry-sur-Seine Cedex, France

Transgenic mouse mutation assays, such as MutaTMMouse (lacZ, CD2F1) and Big Blue® (lacI, B6C3F1), afford the opportunity to evaluate the mutagenic potential of chemicals in any target organ in vivo. This paper discusses published data collected from the analysis of the skin, stomach and lung DNA after topical, oral and inhalation exposure, respectively. These data indicate that both MutaTMMouse and Big Blue® should play an important part in the evaluation of genotoxicity in vivo, particularly where the endpoint or target tissue available in the more conventional tests is inappropriate. It is concluded that there is a distinct role for this type of assay in genetic toxicology testing. For substances applied to the skin or dosed orally or by inhalation and which are unlikely to reach either the bone marrow or the liver, then data derived from these assays may be more relevant to an assessment of possible risk to man than the currently used unscheduled DNA synthesis in liver and cytogenetics assays in bone marrow or peripheral blood.

7 To whom correspondence should be addressed. Tel: +44 1 423 500011; Fax: +44 1 423 569595; Email: stephen.dean{at}covance.com


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 GeneticsHome page
S. Ro and B. Rannala
Inferring Somatic Mutation Rates Using the Stop-Enhanced Green Fluorescent Protein Mouse
Genetics, September 1, 2007; 177(1): 9 - 16.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
A. Besaratinia and G. P. Pfeifer
Investigating human cancer etiology by DNA lesion footprinting and mutagenicity analysis
Carcinogenesis, August 1, 2006; 27(8): 1526 - 1537.
[Abstract] [Full Text] [PDF]

Home page
 MutagenesisHome page
M. S. Turker
Autosomal mutation in somatic cells of the mouse
Mutagenesis, January 1, 2003; 18(1): 1 - 6.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.